infect
play
signific
role
morbid
mortal
elderli
one
popul
infect
adequ
studi
elderli
asthmat
articl
examin
problem
lower
respiratori
tract
infect
elderli
asthmat
context
host
defens
sever
infect
risk
infect
specif
organ
role
infect
pathogenesi
asthma
consider
prophylaxi
therapi
present
bronchial
asthma
gener
consid
diseas
elderli
popul
survey
howev
show
preval
asthma
elderli
rang
lsi
studi
compar
lateonset
asthma
longstand
diseas
nonsmok
elderli
asthmat
braman
et
note
patient
develop
asthma
year
age
review
popul
studi
enright
et
found
preval
asthma
rang
banerje
et
al
note
randomli
select
geriatr
dayhospit
patient
exhibit
airflow
obstruct
pulmonari
function
test
airflow
obstruct
demonstr
greater
improv
peak
expiratori
flow
rate
follow
inhal
addit
chronic
asthma
incid
new
case
year
age
appear
remain
rel
constant
rang
two
six
case
per
thousand
advanc
technolog
nutrit
medicin
set
stage
profound
increas
geriatr
popul
age
group
fastest
grow
segment
societi
north
america
base
current
trend
year
age
group
constitut
popul
industri
nation
thu
anticip
sustain
increas
geriatr
asthmat
requir
care
principl
manag
asthma
elderli
patient
differ
littl
treat
younger
patient
impair
excret
drug
kidney
liver
howev
greater
likelihood
comorbid
diseas
advers
drugdrug
interact
make
manag
asthma
elderli
patient
complex
infectionrel
mortal
elderli
threeto
higher
given
diseas
compar
younger
pneumoniaassoci
mortal
elderli
rang
account
pneumonia
influenza
death
unit
state
influenza
fifth
lead
caus
death
patient
year
recent
prospect
observ
studi
independ
elderli
individu
report
older
year
age
respiratori
tract
infect
bronchiti
pneumonia
influenza
constitut
total
respiratori
infect
sever
lower
respiratori
tract
infect
function
host
suscept
virul
infect
agent
extent
diseas
start
therapi
resist
microbi
invas
lower
respiratori
tract
multifactori
complex
respiratori
tract
immun
system
compos
specif
nonspecif
defens
mechan
consist
varieti
anatom
neurolog
cellular
humor
mechan
integr
mechan
pathogen
virul
size
bacteri
inoculum
play
key
role
colon
subsequ
infect
lower
respiratori
tract
varieti
condit
contribut
alveolar
fluid
accumul
place
host
increas
risk
pneumonia
diminish
host
defens
increas
vulner
elderli
asthmat
patient
protract
debilit
consequ
lung
infect
increas
vulner
may
also
reflect
increas
preval
diseas
associ
fluid
retent
cardiac
renal
liver
failur
swallow
disord
alter
conscious
decondit
due
sedentari
lifestyl
advers
effect
malnutrit
immunosuppress
malign
harford
demonstr
harm
effect
increas
lung
water
surviv
mice
experiment
pneumonia
increas
mortal
describ
mice
inocul
endobronch
bacteria
follow
endobronchi
infus
salin
serum
effect
phagocytosi
occur
condit
absenc
opson
antibodi
diseaserel
pulmonari
dysfunct
associ
increas
frequenc
lower
respiratori
tract
infect
chandra
note
previous
healthi
individu
presenc
anergi
lymphopenia
associ
surviv
rate
respect
longitudin
studi
healthi
elderli
men
decreas
absolut
lympocyt
count
note
within
year
leukopenia
howev
age
depend
studi
might
serv
marker
sever
comorbid
diseas
predomin
healthi
patient
mean
age
year
normal
inflammatori
respons
pneumonia
note
measur
appropri
rise
creactiv
protein
leukocytosi
neutrophil
degranul
product
plasma
neutrophil
elastas
omplex
addit
despit
measur
lower
number
cytotox
lymphocyt
baselin
elderli
patient
abl
mount
adequ
respons
follow
inactiv
influenza
viru
result
support
notion
healthi
elderli
still
abl
mount
adequ
immun
respons
pneumonia
nasopharyng
colon
gramneg
bacteria
report
increas
elderli
patient
studi
look
elderli
live
independ
within
like
high
rate
colon
repres
comorbid
ill
therapi
addit
milieu
patient
resid
elderli
increas
incid
bacteremia
urinari
tract
infect
diverticul
pneumonia
infect
endocard
dissemin
fungal
infect
reactiv
tuberclosi
although
immun
dysfunct
probabl
play
role
infect
increas
suscept
elderli
infect
may
part
repres
synergist
effect
comorbid
ill
nutrit
stat
l
agedepend
organ
dysfunct
saltzman
peterson
jl
note
preval
proteincalori
malnutrit
review
immunodefici
elderli
impair
tcell
respons
anergi
known
immunolog
sequela
malnutrit
may
contribut
immun
dysfunct
elderlyl
l
provis
nutrit
vitamin
trace
element
supplement
week
result
improv
skin
test
respons
increas
tlymphocyt
number
respons
zinc
may
especi
import
anim
studi
involv
zincdefici
mice
demonstr
revers
thymic
involut
tcell
dysfunct
adequ
zinc
replaement
studi
relev
elderli
preval
defici
zinc
intak
measur
zinc
defici
respet
random
control
trial
institution
elderli
administr
mg
zinc
sulfat
twice
daili
result
increas
number
circul
lymphocyt
enhanc
delay
cutan
hypersensit
immunoglobulin
g
respons
tetanu
four
random
doubleblind
placebocontrol
trial
involv
zinc
administr
common
cold
demonstr
decreas
symptom
compar
plaebo
four
addit
random
control
trial
fail
document
clinic
improv
administr
zinc
glucon
common
cold
addit
found
chang
viral
shed
numer
propos
mechan
zinc
might
exert
antimicrobi
clinic
role
yet
work
precis
role
vitamin
replac
establish
clearli
adequ
calor
nutrit
support
import
elderli
chronic
obstruct
lung
diseas
predispos
factor
pneumonia
elderli
asthma
gener
consid
signific
independ
koivula
et
al
lo
howev
populationbas
studi
individu
year
age
finland
note
preval
asthma
compar
patient
develop
pneumonia
adjust
rel
risk
contract
pneumonia
asthmat
confid
interv
ci
rang
suggest
asthma
may
predispos
patient
develop
infect
presenc
lung
diseas
bronchial
asthma
increas
risk
death
postul
mechan
asthma
caus
host
immun
system
dysfunct
review
tabl
l
addit
mucociliari
transport
may
slow
much
acut
exaerb
multipl
author
describ
impair
mucociliari
transport
asthmat
patient
addit
hypogammaglobulinemia
time
like
identifi
unselect
asthmat
normal
p
pl
n
note
patient
hypogammaglobulinemia
receiv
cumul
prednison
dose
equival
mgday
least
year
asthma
elderli
less
like
respons
conserv
therapi
elderli
asthmat
risk
suffer
combin
immunealt
effect
age
comorbid
immunosuppressioni
survey
consecut
geriatr
asthmat
patient
pulmonari
practic
braman
et
note
patient
year
age
requir
oral
steroid
addit
inhal
corticosteroid
highlight
potenti
clinic
signific
iatrogen
immun
defici
previous
describ
immun
host
defens
dysfunct
may
signific
may
less
import
combin
effect
comorbid
diseas
asthmat
patient
year
age
shown
sixto
higher
mortal
younger
patient
partial
attribut
complic
ill
therapi
addit
attribut
delay
present
increas
noncompli
medic
poor
nutrit
isol
live
situat
predispos
poorer
separ
effect
age
comorbid
diseas
suscept
elderli
infect
complex
mani
studi
attempt
identifi
histor
clinic
laboratori
paramet
physician
could
appropri
stratifi
patient
pneumonia
respect
need
hospit
intens
farr
et
review
prognost
factor
obtain
histori
associ
death
pneumonia
identifi
studi
show
associ
older
age
death
nine
studi
found
associ
use
univari
analysi
two
studi
found
associ
use
multivari
recent
studi
evalu
util
radiograph
present
communityacquir
pneumonia
overal
mortal
rate
patient
year
age
older
compar
mortal
rate
patient
year
age
highlight
risk
age
infect
metaanalysi
fine
et
note
cohort
studi
evalu
associ
age
mortal
mean
age
differ
survivor
versu
nonsurvivor
year
studi
logist
regress
analysi
perform
case
note
odd
ratio
ci
rang
death
increment
mean
patient
age
although
metaanalysi
found
age
significantli
associ
death
weight
comorbid
ill
address
studi
esposito
et
black
et
al
lipski
et
correct
comorbid
factor
found
age
signific
risk
factor
mortal
use
retrospect
deriv
prognost
paramet
black
et
note
ambulatori
elderli
patient
like
admit
pneumonia
younger
patient
multivari
analysi
perform
control
comorbid
condit
age
longer
retrospect
case
control
studi
lipski
et
note
dementia
seizur
disord
institution
associ
acquir
pneumococc
infect
studi
age
significantli
associ
pneumococc
pneumonia
correct
comorbid
observ
support
overrid
import
individu
physiolog
statu
determin
initi
invas
lifesav
medic
therapi
precis
relationship
infect
asthma
unclear
previous
mention
koivula
et
allo
show
elderli
asthmat
increas
risk
pneumonia
compar
gener
agematch
popul
suggest
asthma
per
se
may
predispos
elderli
patient
pneumonia
although
tenabl
hypothesi
unclear
whether
comorbid
ill
therapi
corticosteroid
might
prevent
detect
separ
effect
asthma
risk
factor
pneumonia
extens
work
gone
tri
elucid
mechan
infect
may
affect
risk
perpetu
cours
asthma
similarli
total
clear
whether
asthmat
patient
differ
incid
worsen
prognosi
viral
bacteri
combin
infect
mani
studi
evalu
role
preced
viral
infect
develop
airway
hyperrespons
children
role
infect
pathogenesi
asthma
exacerb
adult
continu
controversi
studi
separ
bronchial
asthma
chronic
obstruct
pulmonari
diseas
henc
clinic
data
demonstr
whether
asthma
predispos
one
develop
respiratori
tract
infect
studi
address
bronchial
asthma
independ
comorbid
koivula
et
allo
note
bronchial
asthma
second
alcohol
risk
pneumonia
studi
involv
elderli
independ
finn
show
asthmat
adjust
rel
risk
pneumonia
hospit
ci
rang
ci
rang
respect
compar
remaind
popul
increas
risk
remain
statist
signific
multivari
analysi
signific
comorbid
need
studi
area
bacteri
infect
minim
inappar
role
asthma
exacerb
except
recent
describ
associ
chlamydia
pneumonia
develop
studi
involv
young
asthmat
mcintosh
et
found
differ
bacteri
isol
rate
pneumococcu
hemophilu
influenm
phemolyt
streptococci
staphylococci
auyeu
enter
bacteria
look
symptomat
versu
asymptomat
asthmat
sever
studi
suggest
possibl
role
mycoplasma
pneumonia
develop
asthma
exacerb
studi
involv
wheez
asthmat
month
year
age
gil
et
abl
isol
pneumonia
subject
compar
control
sever
studi
associ
mycoplasma
sp
asthma
clinic
import
still
studi
adult
hudgel
et
confirm
result
find
differ
bacteri
isol
rate
compar
symptomat
versu
asymptomat
asthmat
addit
berman
et
use
transtrach
biopsi
correl
bacteri
isol
exacerb
compar
symptomat
versu
asymptomat
asthmat
studi
look
antimicrobi
therapi
acut
exacerb
asthma
found
differ
outcom
receiv
antibiot
exclus
secondarili
infect
upper
respiratori
infect
bacteri
infect
appear
play
minim
role
asthma
exacerb
therefor
antimicrobi
seldom
indic
c
pneumonia
caus
number
respiratori
nonrespiratori
inflammatori
condit
seropreval
popul
rang
posit
older
patient
prospect
studi
involv
wisconsin
outpati
hahn
et
also
assess
associ
c
pneumonia
infect
wheez
asthmat
bronchiti
adultonset
asthma
prospect
phase
three
patient
pneumonia
patient
bronchiti
posit
serolog
c
pneumonia
infect
patient
three
wheez
acut
infect
six
develop
bronchospasm
ensu
month
control
confound
variabl
c
pneumonia
titer
associ
odd
ratio
ci
rang
develop
wheez
match
control
phase
studi
c
pneumoniaeposit
patient
compar
control
diagnos
asthma
odd
ratio
ci
rang
find
substanti
demonstr
doserespons
relationship
titer
presenc
wheez
c
pneumonia
titer
associ
odd
ratio
wheez
signific
signific
respect
eighti
percent
patient
diagnos
asthma
follow
ill
c
pneurnonia
titer
equal
six
develop
chronic
asthma
follow
bronchiti
one
follow
pneumonia
asthmat
bronchiti
like
occur
older
reinfect
patient
rais
question
whether
c
pneumonia
might
exert
immunemedi
effect
lung
followup
studi
compos
asthmat
without
chronic
obstruct
pulmonari
diseas
copd
hahn
report
c
pneumonia
seroreact
asthmat
seroreact
asthmat
bronchiti
patient
without
anteced
asthma
seroreact
patient
nonwheez
respiratori
ill
addit
studi
similar
result
associ
c
pneumonia
recent
communitybas
openlabel
treatment
trial
involv
asthmat
patient
mean
c
pneumonia
titer
show
signific
improv
patient
week
vari
antimicrobi
treatment
doxycyclin
azithromycin
erythromycin
reflect
improv
forc
expiratori
volum
second
fev
symptom
nonrespond
like
receiv
inhal
corticosteroid
lower
mean
fev
forc
vital
capac
fvc
ratio
baselin
significantli
longer
histori
asthma
symptom
prior
treatment
interest
studi
hamper
lack
control
arm
associ
signific
impair
pulmonari
function
test
prior
test
nonrespond
arm
g
r
yt
n
found
incid
wheez
asthma
higher
c
pneumonia
pneumonia
viral
respiratori
diseas
respiratori
syncyti
viru
rsv
influenza
b
adenoviru
recent
recognit
associ
c
pneurnonia
asthma
yet
anoth
linkag
infect
inflammatori
condit
exact
implic
chlamydiaasthma
associ
yet
defin
studi
need
character
improv
diagnost
therapeut
option
avail
clinician
children
viral
respiratori
tract
infect
shown
play
signific
role
develop
acut
asthma
well
contribut
pathogenesi
airway
hyperrespons
epidemiolog
studi
children
establish
convinc
link
anteced
viral
respiratori
tract
infect
acut
asthma
exacerb
potenti
caus
agent
pathogen
process
airway
tabl
summar
propos
patho
genic
mechan
viral
infect
exacerb
preexist
asthma
well
caus
airway
hyperreact
viral
infect
shown
decreas
peak
flow
induc
airway
epitheli
damag
therebi
potenti
increas
antigen
exposur
host
j
may
result
increas
airway
reactiv
normal
genet
predispos
l
viral
infect
influenza
vaccin
shown
caus
nonspecif
bronchial
hyperrespons
asthmat
henc
although
clinic
experiment
evid
support
causal
link
neonat
childhood
rsv
infect
bronchiol
subsequ
asthma
conflict
evid
occur
epidemiolog
studi
address
possibl
role
viral
infect
asthma
exacerb
pattemor
et
review
epidemiolog
viral
ill
asthma
note
four
studi
children
identifi
significantli
elev
viru
isol
rate
symptomat
asthmat
compar
asymptomat
asthmat
loo
rhinovirus
associ
major
case
virusmedi
infect
asthma
rsv
parainfluenza
adenoviru
influenza
viru
coronaviru
compris
remaind
l
induc
rhinoviru
infect
adult
allerg
ragwe
note
increas
airway
reactiv
allergen
histamin
provoc
addit
eight
patient
experienc
greater
declin
fev
within
hour
antigen
challeng
longitudin
studi
adult
asthmat
year
age
nicholson
et
identifi
nonbacteri
pathogen
asthma
exacerb
associ
cold
symptom
twentyfour
percent
laboratoryconfirm
infect
associ
signific
airflow
obstruct
studi
viral
pathogen
account
infect
rhinoviru
coronaviru
account
major
children
identif
rate
exacerb
approach
viral
respiratori
tract
infect
like
play
role
adult
exacerb
lesser
extent
viral
identif
rate
exacerb
adult
rang
minor
et
hudgel
et
note
viral
isol
rate
adult
significantli
lower
rate
children
versu
lzi
small
lemansk
et
prospect
studi
involv
adult
asthmat
year
age
beasley
et
report
overal
viral
isol
rate
lo
increas
associ
sever
asthma
exacerb
fev
peak
expiratori
flow
rate
sixti
percent
viral
respiratori
tract
infect
associ
acut
asthma
exacerb
studi
exacerb
asthmat
found
asthma
exacerb
associ
symptomat
respiratori
tract
infect
respiratori
tract
infect
associ
asthma
exacerb
studi
viralassoci
asthma
exacerb
protract
cours
exacerb
unassoci
viral
ill
uncompl
viral
respiratori
tract
infect
day
versu
day
versu
day
respect
although
isol
rate
adult
significantli
lower
children
studi
support
notion
virus
contribut
exacerb
bronchial
hyperreact
adult
well
children
studi
report
associ
anteced
viral
infect
asthma
tarlo
et
allso
isol
viru
adult
asthma
exacerb
present
symptom
upper
respiratori
tract
infect
rate
ident
isol
rate
asymptomat
individu
similarli
sokhandan
et
obtain
nasal
swab
viral
isol
adult
asthma
exacerb
necessit
emerg
room
evalu
total
patient
symptom
consist
upper
respiratori
tract
infect
yet
immunofluoresc
cultur
complement
fixat
test
none
evid
viral
infect
sokhandan
cowork
ration
despit
expect
higher
isol
rate
emerg
room
present
compar
rate
note
ambulatori
clinic
lower
rate
rais
signific
question
role
viral
infect
adult
asthma
exacerb
henc
solid
yet
conflict
data
concern
viralmedi
exacerb
asthma
adult
littl
specif
data
elderli
aspergillu
affect
asthmat
host
sever
patholog
mechan
may
caus
profound
allerg
reaction
atop
individu
preexist
bronchial
asthma
may
coexist
colon
respiratori
mucosa
may
progress
sever
invas
aspergillosi
allerg
bronchopulmonari
aspergillosi
abpa
common
allerg
bronchopulmonari
mycosi
character
fever
malais
sputum
product
brown
mucou
plug
pulmonari
eosinophilia
signific
allerg
respons
bronchi
skin
proxim
bronchiectasi
set
establish
asthma
anoth
chronic
lung
diseas
cystic
clinic
cours
vari
mild
asthma
exacerb
sever
pulmonari
fibrosi
follow
year
repeat
inflammatori
episod
hinson
et
first
describ
abpa
syndrom
three
patient
recurr
asthma
peripher
eosinophilia
fever
sputum
product
abnorm
chest
aspergillu
fumigatu
later
grew
sputum
cultur
associ
furnigatu
abpa
subsequ
well
document
although
furnigatu
respons
major
case
syndrom
may
occasion
caus
aspergillu
spp
well
addit
diagnost
consider
fumigatusneg
patient
compat
clinic
syndrom
pseudoallescheria
boydii
candida
albican
curvularia
lunata
rhizopu
spp
helminthosporium
spp
penicillium
spp
stemphylium
spp
torulopsi
glabrata
bipolari
spp
hawaiiensi
fusarium
vasinfecno
formal
studi
evalu
preval
abpa
elderli
recent
studi
asthmat
preselect
posit
immedi
furnigatu
skin
test
howev
patient
fulfil
clinic
criteria
episod
proxim
bronchiectasi
radiograph
interpret
studi
age
group
account
studi
popul
yet
respons
abpa
diagnos
addit
patient
diagnosi
abpa
studi
compar
patient
younger
year
age
preliminari
inform
highlight
potenti
clinic
signific
abpa
elderli
popul
henc
enforc
need
consid
abpa
patient
evalu
summari
infect
clearli
signific
role
asthma
although
evid
link
viral
infect
asthma
exacerb
pathogenesi
convinc
children
less
convinc
adult
epidemiolog
studi
review
focu
elderli
popul
henc
requir
extrapol
associ
virusmedi
airway
hyperrespons
children
younger
adult
consider
elderli
patient
area
need
work
one
time
bacteri
infect
consid
like
caus
asthmat
exacerb
howev
except
recent
propos
associ
c
pneumonia
asthma
lesser
degre
pneumonia
bacteria
consid
play
minor
role
recurr
episod
airway
hyperrespons
children
adult
alik
methodolog
limit
easili
identifi
infect
agent
caus
lower
respiratori
tract
infect
sever
limit
progress
area
perhap
import
insight
role
prior
respiratori
viral
infect
secondari
bronchial
reactiv
provid
studi
prior
viral
infect
patient
sinus
otiti
media
eleg
studi
avail
examin
cultur
antigen
detect
serolog
confirm
middl
ear
sinu
aspir
specimen
shown
clear
associ
primari
viral
secondari
bacteri
infect
sinus
middl
unlik
normal
steril
milieu
sinus
middl
ear
lower
respiratori
tract
lie
distal
heavili
colon
oropharynx
thu
impair
precis
microbiolog
assess
clarif
exact
relationship
viral
bacteri
combin
infect
bypass
contamin
oropharynx
consid
multitud
infecti
agent
expens
methodolog
complex
defin
infect
nose
oropharynx
lung
gastrointestin
tract
amaz
know
much
asthmat
await
better
assess
microbi
infect
wane
immun
cite
potenti
correct
host
defens
defect
despit
avail
vaccin
viral
influenza
streptococcu
pneumonia
import
protect
measur
often
omit
viral
influenza
vaccin
given
year
late
fall
pneumococc
vaccin
especi
import
protect
invas
pneumococc
infect
current
formul
includ
antigen
multidrugresist
strain
would
difficult
treat
antibiot
unfortun
sever
ill
patient
comorbid
diseas
immunocompromis
elderli
substanti
less
like
respond
vaccin
pneumococc
immun
usual
given
year
age
given
younger
age
patient
cardiac
pulmonari
renal
hepat
diseas
would
increas
suscept
invas
pneumococc
diseas
controversi
desir
repeat
vaccin
dermal
reactiv
reimmun
seldom
problem
year
age
howev
elderli
without
comorbid
diseas
show
statist
impair
immunolog
respons
fiveyear
efficaci
immunocompet
consid
data
conced
definit
studi
elderli
asthmat
unlik
becom
avail
seem
prudent
provid
pneumococc
immun
elderli
asthmat
patient
basi
underli
diseas
ie
cardiovascular
disord
chronic
pulmonari
diseas
renal
failur
alcohol
hematopoiet
malign
begin
year
age
vulner
patient
comorbid
diseas
consid
repeat
immun
approxim
interv
better
vaccin
better
instrument
test
efficaci
elderli
need
elderli
patient
asthma
greater
risk
seriou
sequela
viral
infect
measur
like
reduc
risk
viral
infect
societ
practic
also
contribut
enhanc
respiratori
infect
elderli
vulner
patient
group
togeth
nurs
home
often
subject
affection
effus
reunion
famili
children
grandchildren
carrier
infecti
microb
circul
rapidli
among
suscept
resid
adult
approxim
four
viral
infect
per
year
children
averag
six
eight
per
year
thu
wise
grandpar
greatgrandpar
avoid
contact
children
like
activ
viral
infect
logic
often
unaccept
choic
rhinovir
ill
often
transmit
infecti
nasopharyng
secret
therefor
potenti
amen
reduct
barrier
precaut
frequent
hand
wash
return
babi
parent
need
attent
runni
nose
lay
press
suggest
improv
handwash
practic
nurseri
school
reduc
cold
home
nearli
thesi
given
credibl
studi
document
transmiss
virus
fomit
hand
volunt
frequenc
children
adult
pick
nose
rub
eye
infect
virus
inocul
onto
nasal
rnucosa
conjnctiva
thu
appropri
attent
handwash
dispos
soil
tissu
interrupt
transmiss
infect
nasopharyng
secret
benefit
elderli
common
sens
benefit
cover
mouth
cough
recogn
reduc
risk
transmiss
tuberculosi
also
applic
reduc
transmiss
certain
viral
infect
need
document
expand
repertoir
way
interrupt
transmiss
viral
infect
elderli
infirm
patient
risk
respiratori
infect
also
associ
vocat
recreat
exposur
geograph
exposur
risk
factor
associ
respiratori
diseas
hostspecif
asthmat
patient
shown
tabl
seem
prudent
advis
physician
care
vulner
elderli
asthmat
help
prevent
fluid
retent
secondari
cardiac
renal
liver
failur
risk
aspir
due
hiatal
hernia
gastroesophag
reflux
presbyesophag
swallow
disord
thought
evalu
advic
precaut
eat
sleep
safe
swallow
techniqu
discuss
previous
asthmat
patient
respiratori
diseas
usual
asthma
link
bacteri
infect
help
antibiot
sputum
purul
associ
eosinophilrich
exud
viral
infect
confound
diagnost
assess
likewis
criteria
assess
sever
need
hospit
asthma
attack
well
defin
distinct
diagnost
assess
criteria
hospit
pneumonia
articl
address
issu
relev
lower
respiratori
tract
infect
elderli
patient
happen
asthma
instanc
concomit
asthma
littl
effect
common
bacteri
caus
pneumonia
group
rare
instanc
protract
therapi
high
dose
corticosteroid
may
reactiv
tuberculosi
opportunist
fungal
nocardia
infect
likewis
pneumocysti
carinii
infect
complic
highdos
corticosteroid
therapi
rel
normal
host
well
keep
situat
mind
extrem
rare
tabl
diagnosi
respiratori
infect
elderli
base
statist
probabl
specif
infect
consid
host
vulner
epidemiolog
risk
clinic
present
therapi
base
clinic
clue
laboratori
evalu
assess
sever
patient
ill
caus
communityacquir
pneumonia
vari
patient
age
comorbid
diseas
disabl
exposur
infecti
agent
pneumonia
gener
attribut
pneumonia
h
influenm
lo
gramneg
bacilli
lo
aureu
legionella
c
pneumonia
viral
pneumonia
aspir
caus
pneumonia
unknown
patient
frequenc
combin
infect
probabl
higher
recogn
kauppinen
cowork
suggest
mix
infect
may
occur
third
patient
hospit
c
lieberman
cow
r
k
e
r
report
agespecif
etiolog
data
pneumonia
patient
legionella
c
pneurnonia
latter
statist
compar
figur
cite
grayston
note
increas
incid
c
pneurnonia
elderli
find
special
relev
elderli
asthmat
patient
might
expect
higher
likelihood
worsen
asthma
prolong
ill
c
pneurnonia
infect
seri
eleg
studi
document
risk
factor
associ
sever
pneumonia
bad
featur
histori
physic
examin
laboratori
assess
associ
sever
pneumonia
requir
hospit
often
admiss
intens
care
unit
follow
age
year
comorbid
copd
diabet
mellitu
malign
immunodehospit
within
prior
year
postsplenectomi
chronic
alcohol
malnutrit
immunosuppress
physic
examin
respir
breath
per
minut
shock
blood
pressur
mm
hg
temperatur
greater
alter
conscious
confus
extrapulmonari
sign
diseas
mening
endocard
arthriti
white
blood
cell
count
less
band
signific
elev
band
pao
mm
hg
mm
hg
room
air
elev
creatinin
bun
hematocrit
less
hgb
less
gdl
acidosi
dissemin
intravascular
coagul
prolong
prothrombin
time
partial
thromboplastin
time
thrombocytopenia
lobar
pneumonia
multipl
lobe
pneumonia
cavit
effus
empyema
rapid
radiograph
progress
aureu
gramneg
bacilli
aspir
polymicrob
origin
labor
breath
inabl
mobil
secret
rapidli
progress
cours
necessit
evalu
intub
ventilatori
assist
sicker
vulner
patient
requir
aggress
ficienc
fluid
retent
heart
liver
renal
diseas
laboratori
find
diagnost
workup
includ
bronchoscopi
aspir
parapneumon
effus
monitor
assess
intens
care
unit
clinic
predict
rule
mortal
patient
communityacquir
pneumonia
recent
weight
point
system
base
number
advers
indic
appli
calcul
patient
mortal
risk
work
signific
advanc
provid
improv
structur
test
treatment
decis
patient
pneumonia
addit
contribut
made
regard
indic
mild
diseas
permit
ambulatori
treatment
patient
pneumonia
criteria
support
appropri
outpati
therapi
includ
youth
lack
comorbid
diseas
absenc
featur
indic
sever
infect
especi
virul
pathogen
age
less
year
take
medic
depend
commun
diseas
worsen
lack
host
defens
defect
associ
cardiac
renal
liver
failur
cerebrovascular
diseas
debil
due
malign
chronic
lung
diseas
immunosuppress
nurs
home
resid
object
featur
suggest
mild
diseas
histor
physic
find
nonprogress
clinic
cours
normotens
normotherm
alert
orient
patient
normal
respiratori
rate
puls
less
sign
extrapulmon
sepsi
laboratori
find
normal
oxygen
acidbas
balanc
hemoglobin
level
postintervent
pefr
fev
greater
baselin
valnorm
platelet
white
blood
cell
differenti
leukocyt
normal
renal
function
coagul
valu
minim
bronchopneumonia
without
pleural
effus
cavitaprob
lowrisk
pathogen
ue
count
tion
empyema
emphas
clinic
judgment
supersed
guidelin
broader
applic
await
test
interestingli
bronchial
asthma
associ
advers
suggest
antimicrobi
therapi
patient
requir
hospit
communityacquir
pneumonia
nice
summar
recent
work
american
thorac
societi
bartlett
mundyyr
empir
therapi
elderli
patient
requir
hospit
pneumonia
usual
includ
cephalosporin
treat
pneumococc
hemophilu
strain
macrolid
without
rifampin
legionella
patient
risk
gramneg
bacillari
staphylococc
aspir
pneumonia
treat
regimen
shown
tabl
hypotens
critic
ill
patient
also
receiv
vancomycin
sever
ill
patient
requir
broader
coverag
accord
risk
specif
diseas
similarli
patient
risk
multipl
pathogen
like
legionella
mycoplasma
c
pneumonia
plu
concomit
bacteri
diseas
requir
erythromycin
anoth
macrolid
doxycyclin
parenter
fluoroquinolon
addit
specif
coverag
pneumonia
bacteria
like
present
antipneumococc
coverag
alway
necessari
frequenc
pneumococc
pneumonia
multidrugresist
pneumococc
pneumonia
probabl
treat
adequ
highdos
cephalosporin
patient
risk
concomit
endocard
mening
endophthalm
may
requir
concomit
parenter
vancomycin
meropenem
rifampin
terythromycin
azithromycin
clarithromycin
plactamas
inhibitor
combin
ampicillinsulbactam
ticarcillinciavulan
piperacillintazobac
fluoroquinolon
ciprofloxacin
levofloxacin
trovofloxacin
ilaminoglycosid
parenter
fluoroquinolon
ad
ceftriaxon
cefotaxim
lflmipenem
meropenem
indic
sever
ill
immunocompromis
patient
risk
nosocomi
infect
patient
comorbid
diseas
diagnos
treat
accord
risk
specif
diseas
complic
organ
failur
patient
aid
neutropenia
leukemia
organ
transplant
requir
evalu
opportunist
infect
sever
ili
patient
requir
invas
diagnost
studi
tt
patient
gramneg
bacillari
pneumonia
caus
pseudornona
aefuginosa
klebsiella
pneumonia
enferobact
sefrafia
spp
receiv
two
antibiot
effect
suspect
pathogen
usual
plactam
plu
aminoglycosid
parenter
ciprofloxacin
depend
renal
dysfunct
prior
antibiot
therapi
patient
organ
failur
shock
receiv
two
agent
effect
primali
pathogen
plu
therapi
intracellular
pathogen
like
legionella
spp
pneumonia
c
pneumonia
yu
md
person
commun
april
j
patient
pneumonia
promin
wheez
exacerb
asthma
infect
treatment
includ
coverag
c
pneumonia
diagnosi
confirm
llliyoung
overtli
healthi
patient
minim
bronchopneumonia
infiltr
indic
seriou
diseas
treat
macrolid
outpati
use
elderli
nonmenstru
patient
hypotens
patient
organ
failur
fulmin
infect
receiv
broadli
base
empir
therapi
diagnost
studi
permit
institut
pathogenspecif
therapi
patient
multidrugresist
pathogen
increas
problem
therapi
must
individu
equal
import
rapidli
progress
pneumonia
may
occur
bacteremia
infect
caus
pyogen
plagu
primari
viral
influenza
staphylococc
pneumonia
complic
viral
influenza
primari
fungal
pneumonia
blastomycosi
histoplasmosi
coccidioidomycosi
cryptococcosi
rare
caus
fulmin
infect
perhap
common
fulmin
pneumonia
elderli
bacterem
pneumococc
pneumonia
may
present
abruptli
shock
absenc
cough
sputum
product
mani
area
countri
strain
intermedi
highlevel
resist
penicillin
therefor
penicillin
longer
drug
choic
primari
treatment
suspect
pneumococc
pnemonia
pneumococc
pneumonia
caus
strain
intermedi
penicillin
sensit
less
pgml
treat
cephalosporin
like
ceftriaxon
gday
cefotaxim
day
patient
mening
fulmin
pneumococc
infect
treat
vancomycin
plu
cefotaxim
ceftriaxon
sensit
data
becom
avail
import
rememb
ceftizoxim
less
activ
cefotaxim
ceftriaxon
penicillinresist
pneumoccci
suggest
cefotaxim
dosag
increas
g
daili
treat
critic
ill
patient
margin
sensit
applic
approach
requir
studi
elderli
asthmat
patient
pneumonia
usual
hospit
greater
risk
seriou
infect
need
admiss
base
evid
sever
infecti
diseas
sever
asthma
patient
overtli
well
indic
mild
diseas
clinic
stabl
howev
may
treat
outpati
follow
c
r
e
fl
l
although
algorithm
approach
triag
elderli
patient
may
give
sens
fals
secur
healthi
elderli
patient
posttreat
fev
peak
expiratori
flow
rate
pefr
greater
previou
best
predict
may
consid
outpati
elig
ambulatori
care
requir
cooper
depend
patient
adequ
support
system
verifi
patient
take
retain
medicin
ie
vomit
respond
ambulatori
antibiot
therapi
oral
antibiot
elderli
asthmat
patient
pneumonia
must
provid
adequ
coverag
pneumonia
h
infuena
broaderspectrum
oral
antibiot
like
ampicillinclavulan
cefuroxim
azithromycin
meet
need
altern
combin
therapi
g
parenter
ceftraxion
oral
macrolid
therapi
provid
substanti
coverag
patient
cours
treatment
review
next
day
although
oral
fluoroquinolon
treatment
pneumococc
pneumonia
consid
controversi
past
newer
agent
levofloxacin
may
accept
altern
experi
gain
pneumonia
c
pneumonia
treat
macrolid
doxycyclin
fluoroquinolon
cite
previous
atyp
pneumonia
elderli
asthmat
patient
less
like
due
pneumonia
often
caus
c
pneumonia
latter
infect
may
exacerb
prior
respiratori
diseas
asthmat
patient
caus
pneumonia
present
newonset
diseas
usual
move
slowli
famili
member
caus
complaint
pharyng
sinus
dri
poorli
product
cough
headach
malais
diseas
may
caus
persist
ill
chronic
circul
immun
complex
enhanc
atherosclerot
diseas
elderli
patientsla
magnitud
frequenc
phenomena
clarifi
scientif
seem
prudent
initi
therapi
earli
cours
ill
potenti
benefit
shorten
durat
infect
amelior
effect
asthma
reduc
risk
vascular
diseas
uncompl
pneumonia
caus
pneumonia
h
infuenza
pneumonia
usual
treat
adequ
day
c
pneumonia
gener
treat
day
azithromycin
day
agent
legionella
pneumonia
compromis
patient
may
requir
day
treatmentla
concern
use
fluoroquinolon
primari
treatment
respiratori
tract
fluoroquinolon
contraind
pregnanc
therefor
use
sexual
activ
women
whose
risk
pregnanc
uncertain
ciprofloxacin
known
impair
clearanc
theophyllin
use
close
monitor
theophyllin
blood
sparfloxacin
increas
risk
photosensit
levofloxacin
sparfloxacin
affect
theophyllin
metabol
greater
experi
requir
demonstr
efficaci
altern
parenter
therapi
elderli
asthmat
pneumonia
new
fluoroquinolon
less
activ
ciprofloxacin
pseudomona
aevuginosa
fastidi
gramneg
aerob
ciprofloxacin
fluoroquinolon
choic
pathog
e
n
use
conjunct
anoth
effect
parenter
agent
hospit
patient
class
fluoroquinolon
lack
depend
efficaci
stenotrophornona
nocardia
spp
fluoroquinolon
antivir
antifung
activ
use
singledrug
therapi
mycobacteri
infect
place
new
fluoroquinolon
treatment
polymicrobi
anaerob
infect
fulmin
pneumonia
establish
breadth
spectrum
activ
fluoroquinolon
respons
widespread
misus
enthusiasm
use
obscur
fact
overus
increas
risk
emerg
fluoroquinolon
resist
therebi
jeopard
futur
even
better
fluoroquinolon
current
develop
need
reiter
import
defin
like
microbi
caus
pneumonia
prior
select
antibiot
erad
pathogen
caus
infect
focus
patient
risk
infect
pathogen
caus
make
easier
identifi
appropri
diagnost
studi
remain
alert
error
diagnosi
treatment
viral
respiratori
diseas
elderli
asthmat
patient
essenti
patient
compar
age
debil
ill
viral
influenza
amelior
earli
treatment
either
amantadin
rimantidin
amantadin
primarili
excret
kidney
dose
adjust
reflect
reduc
renal
function
ordinari
amantadin
dose
mg
twice
daili
usual
adjust
mg
daili
elderli
renal
impair
patient
rimantidin
excret
primarili
liver
dosag
need
adjust
renal
dysfunct
patient
fulmin
influenza
influenza
b
respiratori
syncyti
viral
rsv
infect
success
treat
inhal
ribavirin
experi
larg
limit
sever
ill
patient
requir
ventilatori
assist
intens
care
unit
patient
unusu
sever
host
defens
defect
owe
liver
lung
bone
marrow
transplant
women
third
trimest
pregnanc
sick
patient
ostens
normal
host
experi
rsv
pneumonia
bone
marrow
transplant
recipi
suggest
treatment
within
first
day
ill
prior
onset
clearcut
respiratori
insuffici
requir
modifi
nearli
mortal
seen
treatment
given
inhal
procedur
higherdos
treatment
given
four
time
daili
current
experi
suggest
concomit
intraven
gamma
globulin
administr
help
bone
marrow
transplant
patient
rsv
although
elderli
patient
known
increas
risk
sever
rsv
influenza
influenza
b
infect
elderli
patient
infect
go
undiagnos
receiv
ribavirin
therapi
ribavirin
therapi
thought
potenti
use
therapeut
altern
critic
ill
elderli
patient
whose
cours
suggest
rsv
influenza
b
infect
likewis
patient
primari
herp
simplex
pneumonia
chickenpox
pneumonia
cytomegalovir
pneumonia
benefit
appropri
antivir
therapi
acyclovir
gancyclovir
foscarn
ill
rare
elderli
asthmat
patient
need
consid
context
concomit
ill
leukemia
lymphoma
acquir
immunodefici
syndrom
therapi
fungalmedi
hypersensit
abpa
may
occur
complic
asthma
cystic
fibrosi
patient
usual
requir
protract
therapi
prednison
diseas
often
relaps
prednison
dose
reduc
treatment
antifung
agent
limit
inabl
current
antimicrobi
erad
aspergillu
bronchopulmonari
tissu
least
three
nonrandom
studi
howev
demonstr
benefit
oral
itraconazol
therapi
coupl
steroid
reflect
reduct
serum
immunoglobulin
e
eosinophilia
improv
fev
therapi
itraconazol
studi
support
adjunct
role
itraconazol
may
permit
reduct
rare
cessat
prednison
abpa
therapi
control
trial
need
document
valid
content
likewis
evalu
newer
potent
therapi
aspergillu
pulmonari
infect
badli
need
conclus
asthma
underrecogn
geriatr
popul
special
consider
although
data
lack
elderli
epidemiolog
studi
younger
age
group
strongli
suggest
caus
provoc
role
infect
asthma
futur
evalu
must
perform
better
character
role
viral
bacteri
infect
geriatr
popul
role
c
pneurnonia
infect
asthma
better
defin
specif
therapi
may
possibl
normal
lung
defens
mechan
declin
age
clinic
diseas
therapeut
strategi
depend
organ
dysfunct
underli
comorbid
diseas
thu
assess
specif
therapi
depend
individu
physiolog
health
rather
chronolog
age
select
therapi
base
host
vulner
epidemiolog
risk
infect
sever
patient
infect
virul
potenti
pathogen
although
conced
import
antimicrobi
therapi
infect
occur
one
must
continu
stress
import
good
hygien
adequ
nutrit
proper
surveil
patient
asthma
vigil
use
vaccin
prevent
infect
asthmat
patient
